EHA abstracts IDH-mutaties
Ivosidenib monotherapy in IDH1 mutated myelodysplastic syndrome, final results of theIDIOME trial, a GFM study Abstract Clinical implications of IDH mutations (IDH MT) in patients (PTS) with higher-risk myelodysplastic syndromes/neoplasms (MDS) treated with hypomethylating agents (HMA) Abstract Clinical outcomes of concurrent FLT3 inhibitor and IDH inhibitor therapy in patients with acute myeloid leukemia Abstract Patient involvement … Continued